Related Experiment Video
Updated: Dec 8, 2025
10:45
Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
Published on: May 25, 2017
14.9K
Alcohol-related liver diseases (ALD)
Vnitrni Lekarstvi
|September 18, 2020
Summary
This review contrasts European Association for the Study of Liver (EASL) guidelines on alcohol-related liver diseases (ALD), emphasizing prevention of alcohol use disorders (AUD) and updating terminology.
Area of Science:
- Hepatology
- Public Health
- Addiction Medicine
Background:
- Alcohol-related liver diseases (ALD) encompass a spectrum of conditions.
- Previous European Association for the Study of Liver (EASL) guidelines were published in 2012.
- Evolving understanding necessitates updated clinical practice recommendations.
Purpose of the Study:
- To review and contrast the 2018 EASL clinical practice guidelines with the 2012 guidelines.
- To highlight changes in terminology for alcohol-related liver diseases (ALD).
- To emphasize the role of prevention for alcohol use disorders (AUD) across healthcare stages.
Main Methods:
- Narrative review of clinical practice guidelines.
- Comparative analysis of EASL guidelines from 2012 and 2018.
- Inclusion of historical, epidemiological, metabolic, and clinical aspects of ALD.
Main Results:
- Significant updates in terminology for alcohol-related liver diseases (ALD) were introduced in the 2018 guidelines.
- The 2018 guidelines place a stronger emphasis on the prevention of alcohol use disorders (AUD).
- The review covers the history, epidemiology, alcohol metabolism, and clinical presentations of ALD.
Conclusions:
- Clinicians should adopt the updated terminology and recommendations from the 2018 EASL guidelines.
- Proactive prevention strategies for alcohol use disorders (AUD) are crucial at all public health care levels.
- A comprehensive understanding of ALD, from its origins to clinical manifestations, is essential for effective management.
More Related Videos
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
1.7K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
101
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
101
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
126
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
126
01:14Dehydration of Aldols to Enals: Base-Catalyzed Aldol Condensation
6.7K
This lesson delves into the aldol condensation catalyzed by bases, where aldols undergo dehydration to enals. As shown in Figure 1, the β-hydroxy aldehyde formed in a base-catalyzed aldol addition reaction dehydrates on heating to yield an unsaturated carbonyl product, which is commonly referred to as an enal.
6.7K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
104
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
104
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
119
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
119